Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing study of IZCARGO in mucopolysaccharidosis type II
jRCT2031210126Recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Jul 2021
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pabinafusp alfa in mucopolysaccharidosis type 2, sponsored by JCR Pharmaceuticals. Primary endpoints: Developmental assessment over time, T.O.V.A. over time and 12 more. Started Jul 2021; status: recruiting.
02
Drugs
pabinafusp alfa
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on jRCT2031210126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210126.